EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Angiopoietin‐like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride‐rich lipoproteins in humans

Marcello Arca, Elias Björnson iD, Laura D'Erasmo, Alessia Di Costanzo, Simone Bini, Ilenia Minicocci, Daniele Tramontano, Stella Covino, Giuseppe Ciarlo, Manuela Lombardi, Sanni Söderlund, Niina Matikainen und 5 weitere

Journal of Internal Medicine · 2026

DOI: 10.1111/joim.70124 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Internal Medicine, 2026. Verfasst von Marcello Arca und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Triglycerides, Apolipoprotein B-48, Apolipoprotein B-100, Angiopoietin-like Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 2021 Global ANGPTL3 ASPIRE Cardiovascular Competitive Grant Program, the Swedish Heart-Lung Foundation, the Swedish Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Angiopoietin‐like protein 3 (ANGPTL3) is a key circulating regulator of triglyceride metabolism and a promising pharmacological target. The physiological consequences of profound ANGPTL3 deficiency can be explored in individuals with inherited loss‐of‐function (LOF) variants, who show reduced lifetime risk of atherosclerotic cardiovascular disease.

Methods

ApoB48, apoB100 and TG metabolism were investigated in chylomicrons, VLDL1, VLDL2, IDL and LDL in 3 ANGPTL3 LOF homozygotes (undetectable plasma ANGPTL3), 4 LOF heterozygotes (ANGPTL3 45.0 ± 7.4 ng/mL) and 10 matched controls (ANGPTL3 110.5 ± 27.6 ng/mL). Studies were performed under post‐prandial conditions to comprehensively characterize TG transport and apoB‐containing lipoprotein kinetics.

Results

Chylomicron and very‐low‐density lipoproteins (VLDL) production rates were similar in ANGPTL3‐deficient subjects and controls. The defining abnormality in LOF homozygotes was the extremely rapid lipolysis of chylomicrons and VLDL, with circulating residence times of minutes rather than hours and accelerated conversion of VLDL to IDL and LDL. LDL particles in LOF homozygotes were TG‐enriched, cholesterol‐depleted, metabolically heterogeneous and cleared more rapidly than in controls or LOF heterozygotes. LOF heterozygotes showed a less pronounced increase in chylomicron and VLDL lipolysis, with normal IDL and LDL kinetics.

Conclusion

Complete loss of ANGPTL3 results in a rapid acceleration of the triglyceride‐rich lipoprotein lipolysis pathway and promotes the formation of metabolically and compositionally abnormal LDL with accelerated clearance. These findings provide mechanistic insight into ANGPTL3 deficiency and are directly relevant for the development and safety assessment of ANGPTL3‐targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TriglyceridesApolipoprotein B-48Apolipoprotein B-100Angiopoietin-like ProteinsLipoproteinsHumansAngiopoietin-Like Protein 3FemaleChylomicronsMaleLipoproteins, VLDLAdultMiddle AgedLoss of Function MutationPostprandial PeriodHomozygote

Stichwörter der Autor:innen

ANGPTL3 (angiopoietin‐like protein 3)apoBkineticsloss‐of‐function variantstriglyceride‐rich lipoproteins (TRL)

Substanzen

Angiopoietin-Like Protein 3TriglyceridesANGPTL3 protein, humanApolipoprotein B-48Apolipoprotein B-100Angiopoietin-like ProteinsChylomicronsLipoproteins, VLDLLipoproteins

Autor:innen und Institutionen

  • Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
  • Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.
  • San Giovanni di Dio, Fondi Hospital, ASL Latina, Fondi, Italy.
  • Research Programs Unit, Clinical and Molecular Medicine, University of Helsinki, Helsinki, Finland.
  • Endocrinology, Abdominal Center, Helsinki University Hospital, Helsinki, Finland.
  • Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

ORCID-Profile: Elias Björnson

Förderung

  • 2021 Global ANGPTL3 ASPIRE Cardiovascular Competitive Grant Program
  • the Swedish Heart-Lung Foundation
  • the Swedish Research Council
  • Swedish governmental funding of clinical research (ALF)

Zitieren

APA

Arca, M., Björnson, E., D'Erasmo, L., Costanzo, A. D., Bini, S., Minicocci, I., Tramontano, D., Covino, S., Ciarlo, G., Lombardi, M., Söderlund, S., Matikainen, N., Andersson, L., Adiels, M., Taskinen, M. R., Packard, C. J., & Borén, J. (2026). Angiopoietin‐like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride‐rich lipoproteins in humans. Journal of Internal Medicine. https://doi.org/10.1111/joim.70124

Vancouver

Arca M, Björnson E, D'Erasmo L, Costanzo AD, Bini S, Minicocci I, et al. Angiopoietin‐like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride‐rich lipoproteins in humans. Journal of Internal Medicine. 2026. doi:10.1111/joim.70124

BibTeX
@article{Arca2026,
  author = {Arca, Marcello and Björnson, Elias and D'Erasmo, Laura and Costanzo, Alessia Di and Bini, Simone and Minicocci, Ilenia and Tramontano, Daniele and Covino, Stella and Ciarlo, Giuseppe and Lombardi, Manuela and Söderlund, Sanni and Matikainen, Niina and Andersson, Linda and Adiels, Martin and Taskinen, Marja-Riitta and Packard, Chris J and Borén, Jan},
  title = {Angiopoietin‐like protein 3 complete and partial deficiency markedly accelerates apolipoprotein B48 and B100 metabolism in triglyceride‐rich lipoproteins in humans},
  journal = {Journal of Internal Medicine},
  year = {2026},
  doi = {10.1111/joim.70124}
}
Kostenlos starten →